Search Clinical Trials
Sponsor Condition of Interest |
---|
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
Hsiao-Ying Wey
Healthy
Caffeine
Adenosine
Dopamine D2/3 Receptor Availability
This research study aims to determine whether and how caffeine intake affects learning
process through reward feedback compared to placebo. The data acquired from this study
would improve our understanding on the consequence and mechanism of caffeine intake in
the aspect of learning process.
Parti1 expand
This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called [11C]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process. Type: Interventional Start Date: May 2023 |
Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Massachusetts General Hospital
Electronic Cigarette Use
Smoking, Cigarette
Nicotine Dependence
This study investigates the feasibility, acceptability, and short-term effects of
providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did
not quit after smoking cessation treatment provided in the context of lung cancer
screening and do not plan to quit smoking. Thi1 expand
This study investigates the feasibility, acceptability, and short-term effects of providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did not quit after smoking cessation treatment provided in the context of lung cancer screening and do not plan to quit smoking. This open-label single-arm pilot clinical trial will test the impact of EC provision on: 1) study feasibility, 2) EC acceptability, 3) tobacco use behavior (e.g., cigarettes per day, EC use), and 4) biomarkers (e.g., carbon monoxide, cotinine, and anabasine). Participants will be asked to switch from combustible cigarettes to the NJOY ACE 5% nicotine electronic cigarette (EC) for 4 weeks. They will be followed an additional 4 weeks after EC provision ends (to 8 weeks). The first study hypothesis is that more than 40% of eligible smokers who are offered participation in the trial will enroll, and that 75% of enrollees will complete the trial. The second study hypothesis is that participants will report fewer cigarettes smoked per day at the end of 4 weeks of EC provision, relative to their baseline values. Type: Interventional Start Date: Sep 2024 |
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Ref1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in
participants with relapsed or refractory multiple myeloma. expand
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma. Type: Interventional Start Date: Mar 2024 |
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Endometrial Cancer
Ovarian Cancer
Triple Negative Breast Cancer
GastroEsophageal Cancer
Non-small Cell Lung Cancer
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety,
tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid
tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion,
and Part B: tumor specific expansion. expand
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion. Type: Interventional Start Date: Jan 2024 |
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Lev1
Gilead Sciences
Primary Biliary Cholangitis
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in
Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance
to Ursodeoxycholic Acid (UDCA) expand
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Type: Interventional Start Date: Sep 2023 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progr1
Bristol-Myers Squibb
Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
BMS-986278 in Participants with Progressive Pulmonary Fibrosis. expand
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis. Type: Interventional Start Date: Oct 2023 |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-1
Hoffmann-La Roche
Small Cell Lung Cancer
Neuroendocrine Carcinoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will
have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants
with advanced stage small cell lun1 expand
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study. Type: Interventional Start Date: Jan 2023 |
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Cellectis S.A.
B-cell Non-Hodgkin Lymphoma (B-NHL)
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22
administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin
Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical
activity of UCART20x22 and determine the Maximum T1 expand
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). Type: Interventional Start Date: Nov 2022 |
MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
Microvention-Terumo, Inc.
Intracranial Aneurysm
The objective of this study is to generate contemporaneous clinical data to facilitate a
reasonable comparison of the performance of the FRED™ X™ device with the performance of
the FRED™ device. The data generated from this study will be compared to the safety and
effectiveness of the FRED™ device1 expand
The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study. Type: Interventional Start Date: Sep 2022 |
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Ca1
BeiGene
Relapsed/Refractory Multiple Myeloma
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in
combination with dexamethasone and carfilzomib intravenously across two cohorts with a
monotherapy component as well. expand
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well. Type: Interventional Start Date: Sep 2021 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With1
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants
with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced
or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had
disease progression during or follo1 expand
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 will focus on inoperable, locally advanced or metastatic, ER-positive, HER2-positive breast cancer with previous progression to standard-of-care anti-HER2 therapies, of which one was a trastuzumab-and-taxane-based systemic therapy (including in the early setting if recurrence occurred within 6 months of finishing adjuvant therapy) and one was a HER2-targeting antibody-drug conjugate (ADC; e.g., ado-trastuzumab emtansine or trastuzumab-deruxtecan) or a HER2-targeting tyrosine kinase inhibitor (TKI; e.g., tucatinib, lapatinib, pyrotinib or neratinib). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. During Stage 1, participants in each cohort will be randomly assigned to treatment arms. Participants in the control or experimental arms who experience unacceptable toxicity, disease progression as determined by the investigator according to RECIST v1.1, or loss of clinical benefit as determined by the investigator during Stage 1 will be given the option of receiving a different treatment combination during Stage 2, provided they meet eligibility criteria and a treatment arm is open for enrollment. No Stage 2 treatment is currently available. Type: Interventional Start Date: Jun 2021 |
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receivin1
Novartis Pharmaceuticals
Advanced Solid Tumors Which Are cMET-dependent
The purpose of this study is to assess long-term safety and provide continued study
treatment access to eligible participants who are judged by the Investigator to benefit
from continued treatment with capmatinib monotherapy or in combination with other
treatments or with the combination treatment1 expand
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study Type: Interventional Start Date: Jul 2017 |
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell, Inc.
Colorectal Cancer
Pancreatic Cancer
Esophageal Cancer
Gastric Cancer
The overall goal of this feasibility study is to assess the initial safety and efficacy
of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers
(adenocarcinoma) using the LUM Imaging System. expand
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System. Type: Interventional Start Date: Aug 2016 |
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed D1
National Human Genome Research Institute (NHGRI)
Genetic Disease
Without an explanation for severe and sometimes life-threatening symptoms, patients and
their families are left in a state of unknown. Many individuals find themselves being
passed from physician to physician, undergoing countless and often repetitive tests in
the hopes of finding answers and insig1 expand
Without an explanation for severe and sometimes life-threatening symptoms, patients and their families are left in a state of unknown. Many individuals find themselves being passed from physician to physician, undergoing countless and often repetitive tests in the hopes of finding answers and insight about what the future may hold. This long and arduous journey to find a diagnosis does not end for many patients- the Office of Rare Diseases Research (ORDR) notes that 6% of individuals seeking their assistance have an undiagnosed disorder. In 2008, the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) was established with the goal of providing care and answers for these individuals with mysterious conditions who have long eluded diagnosis. The NIH UDP is a joint venture of the NIH ORDR, the National Human Genome Research Institute Intramural Research Program (NHGRI-IRP), and the NIH Clinical Research Center (CRC) (1-3). The goals of the NIH UDP are to: (1) provide answers for patients with undiagnosed diseases; (2) generate new knowledge about disease mechanisms; (3) assess the application of new approaches to phenotyping and the use of genomic technologies; and (4) identify potential therapeutic targets, if possible. To date, the UDP has evaluated 3300 medical records and admitted 750 individuals with rare and undiagnosed conditions to the NIH Clinical Center. The NIH UDP has identified more than 70 rare disease diagnoses and several new conditions. The success of the NIH UDP prompted the NIH Common Fund to support the establishment of a network of medical research centers, the Undiagnosed Diseases Network (UDN), for fiscal years 2013-2020. The clinical sites will perform extensive phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing performed on patients involves medically indicated studies intended to help reach a diagnosis, as well as research investigations that include a skin biopsy, blood draws, and DNA analysis. In addition, the UDN will further the goals of the UDP by permitting the sharing of personally identifiable phenotypic and genotypic information within the network. By sharing participant information and encouraging collaboration, the UDN hopes to improve the understanding of rare conditions and advance the diagnostic process and care for individuals with undiagnosed diseases. Type: Observational Start Date: Sep 2015 |
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
Solid Tumor, Adult
Metastatic Breast Cancer
Advanced Breast Cancer
HER2 Mutation-Related Tumors
HER2-positive Metastatic Breast Cancer
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of
BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients
with advanced solid tumors. expand
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors. Type: Interventional Start Date: Oct 2024 |
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007).
Merck Sharp & Dohme LLC
Carcinoma, Squamous Cell
Skin Neoplasms
This is a two-part (Phase 2/Phase 3) study of V940, an individualized neoantigen therapy
(INT), plus pembrolizumab in participants with locally resectable advanced cutaneous
squamous cell carcinoma (LA cSCC). Phase 2 has three arms V940 plus pembrolizumab given
as neoadjuvant and adjuvant treatment1 expand
This is a two-part (Phase 2/Phase 3) study of V940, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms V940 plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of V940 in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that V940 plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to V940 plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrollment or study endpoints. Type: Interventional Start Date: Apr 2024 |
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants1
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Sclerosis
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug
levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or
Progressive Forms of Multiple Sclerosis (PMS). expand
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS). Type: Interventional Start Date: Mar 2024 |
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With P1
Sanofi
Dermatitis Atopic
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind,
placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with
moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled
with topical prescription therapies1 expand
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600] (ESTUARY). Type: Interventional Start Date: Nov 2023 |
Tocilizumab in Lung Transplantation
National Institute of Allergy and Infectious Diseases (NIAID)
Lung Transplant
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1)
to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance
immunosuppression or placebo (sterile normal saline) plus standard triple maintenance
immunosuppression (Tacrolimus, Myco1 expand
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death Type: Interventional Start Date: Feb 2024 |
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
Astria Therapeutics, Inc.
Hereditary Angioedema
The goal of this trial is to enable the collection of information about long-term safety
and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE).
Participants will receive repeat doses of STAR-0215 for up to 5 years. expand
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years. Type: Interventional Start Date: Sep 2023 |
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
GB002, Inc.
Pulmonary Arterial Hypertension
The primary objective of the study is to determine the effect of seralutinib on improving
exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary
objective for this trial is to determine time to clinical worsening. expand
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening. Type: Interventional Start Date: Dec 2023 |
A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy1
Jazz Pharmaceuticals
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
The purpose of this study is to investigate behavioral and other co-occurring outcomes
with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous
sclerosis complex (TSC) who experience seizures. expand
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures. Type: Interventional Start Date: Jun 2023 |
Assessment of Combined CCM and ICD Device in HFrEF
Impulse Dynamics
Heart Failure
Heart Failure with Reduced Ejection Fraction
Implantable Defibrillator User
CCM Therapy
Non-ischemic Cardiomyopathy
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D
System (the "CCM-D System") can safely and effective convert induced ventricular
fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation
(VT/VF) episodes in subjects with Stage C or1 expand
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years. Type: Interventional Start Date: May 2023 |
Oxytocin Effects on Bone in Children with Autism Spectrum Disorder
Elizabeth Austen Lawson
Autism Spectrum Disorder
Bone Health
This is a randomized, double blind, placebo-controlled study of the effects of intranasal
oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old.
Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times
daily) for 12 months in the double-1 expand
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times daily) for 12 months in the double-blind phase, followed by a 6-month open label phase during which all study subjects will receive intranasal oxytocin (30 IU, 2 times daily). Study visits include screening to determine eligibility, followed by study visits at baseline, week 2, and months 6, 12, 18 and phone calls every two weeks for the first two months and monthly thereafter for the duration of the study. Study assessments include history and physical examinations, anthropometric measurements, electrocardiogram (EKG), adverse event monitoring, laboratory tests for chemistries, hormones and biomarkers for bone metabolism, questionnaires regarding diet and exercise, and imaging to assess body composition, bone density and structure. Type: Interventional Start Date: Aug 2023 |
A Retrospective Assessment of OviTex PRS (OviTex)
Tela Bio Inc
Reconstructive Surgical Procedures
The objective of this retrospective-prospective, observational study is to evaluate the
safety profile overall and within two device types of OviTex PRS in previous pre-pectoral
or sub-pectoral implant-based breast reconstructions. expand
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions. Type: Observational Start Date: Sep 2022 |
- Previous
- Next